Market-View-Feature-Image

View on market: Stay Cautious, be with quality business:

Asian stocks rose Thursday following the best day for U.S. shares this month, while the 10-year Treasury yield held a drop ahead of inflation data that will shape views on Federal Reserve policy tightening. Equities in Japan, Australia and South Korea advanced. U.S. futures fluctuated after the S&P 500 extended a broad rally Wednesday and the Nasdaq 100 jumped over 2%.The Singapore-traded SGX Nifty, an early indicator of India’s Nifty 50 Index’s performance, rose 0.23% to 17,524.50 as of 7:00 a.m. Elsewhere, oil’s rally has stalled around $90 a barrel, in part on the possibility that a nuclear deal with Iran could bring supply relief to a tight market.

Economic Calendar:

  • INR: RBI Credit Policy on 10th February, 2022.
  • INR:  M3 Money Market Supply on 10th  February 2022.
  • USD: Federal Budget Balance on 11th February, 2022.
  • USD: Inflation Data on 10th February, 2022.

Earnings: Mahindra & Mahindra Hindalco Industries Hero MotoCorp Hindustan Aeronautics Zomato Bharat Forge Tata Chemicals ABB India Amara Raja Batteries Page Industries Cummins India Computer Age Management Services General Insurance Corporation of India Krishna Institute of Medical Sciences IRB Infrastructure Developers Indian Railway Finance Corporation Gujarat State Petronet Dr Lal PathLabs Piramal Enterprises Quess Corp Carborundum Universal Alembic Pharmaceuticals Gujarat Pipavav Port Mindspace Business Parks Reit MRF Rashtriya Chemicals & Fertilizers Aegis Logistics BEML ESAB India Bombay Dyeing & Mfg. Co Cochin Shipyard Elgi Equipments GR Infraprojects HealthCare Global Enterprises Honda India Power Products India Nippon Electricals Indo Rama Synthetics (India) Insecticides (India) MTAR

Results:

SAIL: Q3FY22 (Standalone, QoQ) Revenue down 6% at Rs 25,245.92 crore Vs Rs 26,826.92 crore Net profit down 66% at Rs 1,443.10 crore Vs Rs 4,303.62 crore Ebitda down 51% at Rs 3,410.44 crore Vs Rs 7,016.92 crore Margin at 13.5% Vs 26.2%

Tata Power: Q3FY22 (Consolidated, YoY) Revenue up 44% at Rs 10,913.14 crore Vs Rs 7,597.91 crore Net profit up 72% at Rs 425.81 crore Vs Rs 248.21 crore Ebitda down 6% at Rs 1,633.76 crore Vs Rs 1,734.26 crore Margin at 15% Vs 22.83% To set up 4GW solar cell and module manufacturing capacity with an investment of Rs 3,400 crore Solar EPC order book has crossed Rs 10,000 crore

Power Grid Corporation of India: Q3FY22 (Consolidated, YoY) Revenue up 3% at Rs 10,446.88 crore Vs Rs 10,142.48 crore Net profit down 2% at Rs 3,292.97 crore Vs Rs 3,367.71 crore Ebitda up 2% at Rs 9,117.27 crore Vs Rs 8,914.54 crore Margin at 87.3% Vs 87.9% Approved interim dividend of Rs 5.50 per share
Brokerage Radar:

MACQUIRE ON BERGER PAINTS: UW, TP Rs 695 3Q sales beat offset by input cost pressures Another qtr of sales underperformance vs APNT Gross margin down 160bps QoQ for BRGR vs 200bps expansion for APNT, & 50bps expansion for KNPL.

CITI ON AUROBINDO PHARMA: (1st cut) Buy, TP Rs 1020 Weak set – EBITDA/PAT 10%/12% below est Gross margin down by 355bps QoQ to 54.3%, while EBITDA margin was 16.9% (-304bos QoQ, -457bps YoY) According to co, 3Q impacted by high input & freight cost

International Markets:

U.S & Europe

Particulars 9th  Feb Chg Chg(%)
Nasdaq 14,490.37 295.91 2.08
Dow 35768.06 305.28 0.86
FTSE 7,643.42 76.35 1.01
CAC 7,130.88 102.47 1.46
DAX 15,482.01 239.63 1.57
Dow Fut.* 35723.2 -43.9 -0.12

Asian markets:

Particulars 10th  Feb Chg. Chg(%)
SGX Nifty 17,515.50 31.5 0.18
Nikkei 27,598.11 18.24 0.07
Straits Times 3,405.96 -14.08 -0.41
Hang Seng 24,793.43 -36.56 -0.15
Shanghai 3,477.79 -2.16 -0.06

ADR Watch:

Particulars 9th  Feb Chg. Chg.(%)
Dr Reddy 57.26 -0.26 -0.45
HDFC Bank 67.37 -0.01 -0.01
ICICI Bank 21.4 0.22 1.04
Infosys 22.89 0.42 1.87
Tata Motor 32.99 0.19 0.58
Wipro 7.54 0.1 1.34

Commodities & Currency:

Particulars Current Price Chg(%)
USD/INR 74.81 -0.06
Brent 91.41 -0.15
Gold 1834.75 -0.10
Silver 23.242 -0.43

FIIs & DII

Particulars 9th   Feb 8th   Feb
FIIs -892.64 -1967.89
DIIs 1793.35  1115.00 

News Update:

Tata Steel Long Products: The company accepted the Letter of Award for acquisition of Neelachal Ispat Nigam. It will acquire acquire 93.71% equity stake in Neelachal Ispat Nigam and the acquisition process is likely to be completed within the next couple of months.

NHPC: The company has signed a letter of intent with Rajasthan Renewable Energy Corporation for development of 10,000 MW Renewable Energy Projects/ Parks in Rajasthan.

Nuvoco Vistas: The company will augment cement volumes availability by 2.4 MTPA through key project including upgrading Bhiwani Blending Unit to a Grinding Unit. The company will set up alternate fuel material handling facilities at Risda and Nimbol Cement plants with capex of Rs 50 crore. It will also venture in a Greenfield expansion of 6,000TPD

Lupin: The company has entered d into a distribution agreement with Medis for its orphan drug NaMuscla (mexiletine). Medis will commercialize NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders in Central and Eastern European countries.Tartrate Inhalation

Source: Moneycontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL

 

 

FILING COMPLAINTS ON SCORES - EASY & QUICK

a. Register on SCORES portal

b. Mandatory details for filing complaints on SCORES:
i. Name, PAN, Address, Mobile Number, E-mail ID

c. Benefits:
i. Effective communication
ii. Speedy redressal of the grievances

SEBI : https://www.scores.gov.in/scores/complaintRegister.html